Results 11 to 20 of about 530,731 (290)

Engineering a novel IgG-like bispecific antibody against enterovirus A71

Biochemistry and Biophysics Reports, 2020
Frequent outbreaks of enterovirus A71 (EVA71) occur in the Asia-Pacific area, and these are closely associated with severe neurological symptoms in young children. No effective antiviral therapy is currently available for the treatment of EVA71 infection.
Hsiang-Ching Wang, Hui-Chen Hung, Peng-Nien Huang, Yu-An Kung, Sung-Nien Tseng, Yun-Ming Wang, Shin-Ru Shih, John Tsu-An Hsu   +7 more
doaj   +2 more sources

Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy

International Journal of Nanomedicine, 2018
Haitao Pan,1,2 Jiayu Liu,1,2 Wentong Deng,1,2 Jieyu Xing,1,2 Qing Li,1,2 Zhong Wang1,2 1School of Pharmaceutical Sciences, 2Centre for Cellular & Structural Biology, Sun Yat-Sen University, Guangzhou, People’s Republic of China Introduction ...
Pan H, Liu J, Deng W, Xing J, Li Q, Wang Z   +5 more
doaj   +1 more source

Bispecific antibody generated with sortase and click chemistry has broad anti-influenza virus activity [PDF]

, 2014
Bispecific antibodies have therapeutic potential by expanding the functions of conventional antibodies. Many different formats of bispecific antibodies have meanwhile been developed.
Witte, M.D., Wagner, K., Spits, H.G., Claassen, Y.B., Beaumont, T., Cornelissen, A.H.M., Kwakkenbos, M.J., Bohne, M., Maijoor, K., van Zoelen, D.J., van der Sluijs, K.F., Bakker, A.Q., Ploegh, H.L.   +12 more
core   +4 more sources

BISPECIFIC ANTIBODIES

Drug Discovery Today, 2015
Bispecific antibodies have emerged as molecules with a multitude of ...
BENNETT ERIC M, HIGGINSON-SCOTT NATHAN, TCHISTIAKOVA LIOUDMILA, MARQUETTE KIMBERLY A, PAULSEN JANET E, GIMENO RUTH E   +5 more
openaire   +6 more sources

Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency

mAbs, 2023
Antibody CAP256-VRC26.25 targets the second hypervariable region (V2) at the apex of the HIV envelope (Env) trimer with extraordinary neutralization potency, although less than optimal breadth. To improve breadth, we linked the light chain of CAP256V2LS,
Baoshan Zhang, Jason Gorman, Young D. Kwon, Amarendra Pegu, Cara W. Chao, Tracy Liu, Mangaiarkarasi Asokan, Michael F. Bender, Tatsiana Bylund, Leland Damron, Deepika Gollapudi, Paula Lei, Yile Li, Cuiping Liu, Mark K. Louder, Krisha McKee, Adam S. Olia, Reda Rawi, Arne Schön, Shuishu Wang, Eun Sung Yang, Yongping Yang, Kevin Carlton, Nicole A. Doria-Rose, Lawrence Shapiro, Michael S. Seaman, John R. Mascola, Peter D. Kwong   +27 more
doaj   +1 more source

A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies

mBio, 2020
Broadly neutralizing antibodies (bNAbs) can prevent and control an HIV-1 infection, but their breadth is invariably too limited for use as monotherapy. To address this problem, bi- and trispecific antibody-like constructs have been developed.
Meredith E. Davis-Gardner, Barnett Alfant, Jesse A. Weber, Matthew R. Gardner, Michael Farzan   +4 more
doaj   +1 more source

A new approach to produce IgG4-like bispecific antibodies

Scientific Reports, 2021
While achieving rapid developments in recent years, bispecific antibodies are still difficult to design and manufacture, due to mispair of both heavy and light chains. Here we report a novel technology to make bispecific molecules.
Caizhi Zhao, Wei Zhang, Guihua Gong, Liping Xie, Ming-Wei Wang, Youjia Hu   +5 more
doaj   +1 more source

Bispecific antibody therapies

Hematology, 2023
Abstract Management of hematological malignancies is rapidly evolving from chemotherapy-based regimens toward targeted agents and immunotherapies, including bispecific antibodies (BsAbs). These novel and highly active treatments come with new side effect profiles.
de Assis, Luiz Henrique, Fassi, Daniel El, Hutchings, Martin   +2 more
openaire   +3 more sources

Crystal Structure of an Anti-Ang2 CrossFab Demonstrates Complete Structural and Functional Integrity of the Variable Domain. [PDF]

, 2013
Bispecific antibodies are considered as a promising class of future biotherapeutic molecules. They comprise binding specificities for two different antigens, which may provide additive or synergistic modes of action.
Duerr, Harald, Kettenberger, Hubert, Thomas, Markus, Imhof-Jung, Sabine, Fenn, Sebastian, Christian B Schiller, Harald Duerr, Julia J Griese, Griese, Julia J., Sebastian Fenn, Schiller, Christian B., Regula, Joerg Thomas, Sebastian Fenn, Schaefer, Wolfgang, Christian Klein, Klein, Christian, Christian Gassner, Hubert Kettenberger, Markus Thomas, Gassner, Christian, Julia J. Griese, Hopfner, Karl Peter, Wolfgang Schaefer, Christian B. Schiller, Karl-Peter Hopfner, Moelleken, Joerg, Hopfner, Karl-Peter, Joerg Moelleken, Joerg Thomas Regula, Sabine Imhof-Jung   +29 more
core   +2 more sources

A high throughput bispecific antibody discovery pipeline [PDF]

, 2023
A single-cell based bispecific antibody (BsAb) discovery pipeline, based on a microfluidics droplets generation and sorting systems, has the potential to speed up the discovery and development of functional antibodies such as BsAb ...
Yonglei Shang, Xiaoming Chen, Fung, Audrey, Jayaraman, Jayapriya, Zimak, Jan, Zhao, Weian, Ci Ren, Luxon, Ryan, Ren, Ci, Chen, Xiaoming, Ma, Xiaoya, Rivera, Rodrigo, Wu, George, Fu, Qiwei, Jayapriya Jayaraman, Rodrigo Rivera, Weian Zhao, Ryan Luxon, Hedde, Per Niklas, Jonathan Chong, Audrey Fung, Segaliny, Aude I, Aude I. Segaliny, Xiaoya Ma, Per Niklas Hedde, Qiwei Fu, Jiang, Xianzhi, Jan Zimak, Shang, Yonglei, George Wu, Xianzhi Jiang, Chong, Jonathan   +31 more
core   +1 more source